<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960763</url>
  </required_header>
  <id_info>
    <org_study_id>TRD-1511-33321</org_study_id>
    <secondary_id>201609085</secondary_id>
    <nct_id>NCT02960763</nct_id>
  </id_info>
  <brief_title>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to assess which antidepressants work the best in older
      adults who have treatment-resistant depression (TRD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Older adult participants with treatment-resistant depression will be randomly assigned to a
      Step 1 medication strategy.

        -  Adding aripiprazole to current antidepressant medication

        -  Adding bupropion to current antidepressant medication

        -  Replacing current antidepressant medication with bupropion

      If depression is not relieved at the end of 10 weeks, or if participants do not qualify for
      Step 1, participants will be randomly assigned to a Step 2 medication strategy:

        -  Adding lithium to current antidepressant medication

        -  Replacing current antidepressant medication with nortriptyline

      All medication strategies will be offered in collaboration with participants' own physicians
      with the the research team providing support and guidance.

      After treatment in Step 1 and/or Step 2, participants will enter the Continuation Phase to
      assess long term follow-up outcomes for 12 months.

      Participants in this clinical trial will also be asked to participate in an additional study
      to gather imaging and biomarker data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychological Well-Being</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Measured by NIH Toolbox Surveys: Positive Affect and General Life Satisfaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission from Depression</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Remission defined as Montgomery Asberg Depression Rating Scale score â‰¤10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Through study completion (20 weeks, 1 year and 10 weeks, or 1 year and 20 weeks)</time_frame>
    <description>Life threatening illness, hospitalization, or need of medical care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Falls</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Number of falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fall-related Injuries</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Injuries or impairment resulting from falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in executive function</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by composite variable of selected tasks from the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Delis-Kaplan Executive Function System (D-KEFS), and NIH Toolbox-Cognition battery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in episodic memory</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by composite variable of selected tasks from the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Delis-Kaplan Executive Function System (D-KEFS), and NIH Toolbox-Cognition battery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in executive-control and cortico-limbic circuitry</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma biomarkers</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by customized multiplex protein array platform from the Senescence Associated Secretory Protein (SASP) index</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Treatment-Refractory Depression</condition>
  <condition>Late Life Depression</condition>
  <condition>Geriatric Depression</condition>
  <arm_group>
    <arm_group_label>Aripiprazole Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Aripiprazole Augmentation</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Bupropion Augmentation</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to bupropion</intervention_name>
    <description>Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Switch to Bupropion</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.</description>
    <arm_group_label>Lithium Augmentation</arm_group_label>
    <other_name>Lithium carbonate</other_name>
    <other_name>Eskalith</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to nortriptyline</intervention_name>
    <description>Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml</description>
    <arm_group_label>Switch to Nortriptyline</arm_group_label>
    <other_name>Pamelor,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 60 and older

          -  Current Major Depressive Disorder (MDD)

          -  Failure to respond adequately to two or more antidepressant treatment trials of
             recommended dose and length

          -  Patient Health Questionnaire-9 (PHQ-9) score of 6 or higher

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Dementia

          -  Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective
             disorder, schizophreniform disorder, delusional disorder, or current psychotic
             symptoms

          -  High risk for suicide and unable to be managed safely in the clinical trial

          -  Contraindication to proposed study medications, as determined by study physician
             including history of intolerance or non-response to proposed medications.

          -  Non-correctable, clinically significant sensory impairment interfering with
             participation

          -  Unstable medical illness, including delirium, uncontrolled diabetes mellitus,
             hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that
             are not under medical management.

          -  Moderate to severe substance or alcohol use disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Lenard, MSW</last_name>
    <phone>314-747-5706</phone>
    <email>lenarde@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Schweiger, CCRC</last_name>
    <phone>314-362-3153</phone>
    <email>schweigj@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Late-Life Mood, Stress, and Wellness Research Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie St. Cyr, MA</last_name>
      <phone>310-983-3375</phone>
      <email>nstcyr@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Helen Lavretsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Healthy Mind Lab</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Lenard, BA</last_name>
      <phone>314-747-5706</phone>
      <email>lenarde@psychiatry.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Schweiger, BA</last_name>
      <phone>314-362-3153</phone>
      <email>schweigj@psychiatry.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Lenze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Adult and Late Life Depression Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Brown, PhD</last_name>
      <phone>646-774-8666</phone>
      <email>pb2410@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Roose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Stack, RN, MSN, CNS</last_name>
      <phone>412-246-6006</phone>
      <email>StackJA@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jordan Karp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles F Reynolds III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J-1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athina Perivolaris, RN, MN</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32897</phone_ext>
      <email>athina.perivolaris@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Benoit Mulsant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Eric Lenze</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Comparative Effectiveness Research</keyword>
  <keyword>Pragmatic Clinical Trials</keyword>
  <keyword>Patient-Centered Outcomes Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A cleaned, complete, and de-identified copy of the final data set including administrative and technical metadata records will be made available through a Washington University in St. Louis (WUSTL) secure repository and registered at clinicaltrials.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

